161 related articles for article (PubMed ID: 36768721)
1. Antineoplastic Activity of Pazopanib in Anaplastic Thyroid Cancer in Primary Culture.
Ferrari SM; Elia G; Ragusa F; Paparo SR; Mazzi V; Patrizio A; Piaggi S; Baldini E; Centanni M; La Motta C; Antonelli A; Fallahi P
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768721
[TBL] [Abstract][Full Text] [Related]
2. Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle Aspiration.
Ferrari SM; La Motta C; Elia G; Ragusa F; Ruffilli I; Quattrini L; Paparo SR; Piaggi S; Patrizio A; Ulisse S; Baldini E; Materazzi G; Fallahi P; Antonelli A
Front Endocrinol (Lausanne); 2018; 9():764. PubMed ID: 30619094
[TBL] [Abstract][Full Text] [Related]
3. CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.
Fallahi P; Ferrari SM; La Motta C; Materazzi G; Bocci G; Da Settimo F; Miccoli P; Antonelli A
Endocrine; 2016 Jul; 53(1):136-44. PubMed ID: 26286966
[TBL] [Abstract][Full Text] [Related]
4. Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer.
Isham CR; Bossou AR; Negron V; Fisher KE; Kumar R; Marlow L; Lingle WL; Smallridge RC; Sherman EJ; Suman VJ; Copland JA; Bible KC
Sci Transl Med; 2013 Jan; 5(166):166ra3. PubMed ID: 23283368
[TBL] [Abstract][Full Text] [Related]
5. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
Ferrari SM; Bocci G; Di Desidero T; Elia G; Ruffilli I; Ragusa F; Orlandi P; Paparo SR; Patrizio A; Piaggi S; La Motta C; Ulisse S; Baldini E; Materazzi G; Miccoli P; Antonelli A; Fallahi P
Oncol Rep; 2018 May; 39(5):2225-2234. PubMed ID: 29517103
[TBL] [Abstract][Full Text] [Related]
6. New targeted therapies for anaplastic thyroid cancer.
Antonelli A; Fallahi P; Ulisse S; Ferrari SM; Minuto M; Saraceno G; Santini F; Mazzi V; D'Armiento M; Miccoli P
Anticancer Agents Med Chem; 2012 Jan; 12(1):87-93. PubMed ID: 22043992
[TBL] [Abstract][Full Text] [Related]
7. CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.
Antonelli A; Bocci G; La Motta C; Ferrari SM; Fallahi P; Ruffilli I; Di Domenicantonio A; Fioravanti A; Sartini S; Minuto M; Piaggi S; Corti A; Alì G; Di Desidero T; Berti P; Fontanini G; Danesi R; Da Settimo F; Miccoli P
J Clin Endocrinol Metab; 2012 Apr; 97(4):E528-36. PubMed ID: 22278419
[TBL] [Abstract][Full Text] [Related]
8. S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib.
Jiao X; Zhang H; Xu X; Yu Y; Zhang H; Zhang J; Ning L; Hao F; Liu X; Niu M; Chen CT; Chen D; Zhang K
Cell Physiol Biochem; 2018; 49(3):1143-1162. PubMed ID: 30196299
[TBL] [Abstract][Full Text] [Related]
9. CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.
Antonelli A; Bocci G; Fallahi P; La Motta C; Ferrari SM; Mancusi C; Fioravanti A; Di Desidero T; Sartini S; Corti A; Piaggi S; Materazzi G; Spinelli C; Fontanini G; Danesi R; Da Settimo F; Miccoli P
J Clin Endocrinol Metab; 2014 Apr; 99(4):E572-81. PubMed ID: 24423321
[TBL] [Abstract][Full Text] [Related]
10. Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo.
Ferrari SM; Bocci G; Di Desidero T; Ruffilli I; Elia G; Ragusa F; Fioravanti A; Orlandi P; Paparo SR; Patrizio A; Piaggi S; La Motta C; Ulisse S; Baldini E; Materazzi G; Miccoli P; Antonelli A; Fallahi P
Oncol Rep; 2018 May; 39(5):2306-2314. PubMed ID: 29517106
[TBL] [Abstract][Full Text] [Related]
11. A novel therapeutic approach for anaplastic thyroid cancer through inhibition of LAT1.
Enomoto K; Sato F; Tamagawa S; Gunduz M; Onoda N; Uchino S; Muragaki Y; Hotomi M
Sci Rep; 2019 Oct; 9(1):14616. PubMed ID: 31601917
[TBL] [Abstract][Full Text] [Related]
12. Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells.
Wang W; Zhou J; Zhao L; Chen S
Biomed Pharmacother; 2017 Apr; 88():985-990. PubMed ID: 28178630
[TBL] [Abstract][Full Text] [Related]
13. Targeting Super-Enhancer-Driven Oncogenic Transcription by CDK7 Inhibition in Anaplastic Thyroid Carcinoma.
Cao X; Dang L; Zheng X; Lu Y; Lu Y; Ji R; Zhang T; Ruan X; Zhi J; Hou X; Yi X; Li MJ; Gu T; Gao M; Zhang L; Chen Y
Thyroid; 2019 Jun; 29(6):809-823. PubMed ID: 30924726
[No Abstract] [Full Text] [Related]
14. Sorafenib inhibits vascular endothelial cell proliferation stimulated by anaplastic thyroid cancer cells regardless of BRAF mutation status.
Ishihara S; Onoda N; Noda S; Asano Y; Tauchi Y; Morisaki T; Kashiwagi S; Takashima T; Ohira M
Int J Oncol; 2019 Nov; 55(5):1069-1076. PubMed ID: 31545405
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic inhibition of polo-like kinases in anaplastic thyroid cancer.
Lin SF; Yeh CN; Huang YT; Chou TC; Wong RJ
Cancer Sci; 2021 Feb; 112(2):803-814. PubMed ID: 33306266
[TBL] [Abstract][Full Text] [Related]
16. Multimodal treatments and outcomes for anaplastic thyroid cancer before and after tyrosine kinase inhibitor therapy: a real-world experience.
Park J; Jung HA; Shim JH; Park WY; Kim TH; Lee SH; Kim SW; Ahn MJ; Park K; Chung JH
Eur J Endocrinol; 2021 May; 184(6):837-845. PubMed ID: 33852431
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer.
Fan D; Ma J; Bell AC; Groen AH; Olsen KS; Lok BH; Leeman JE; Anderson E; Riaz N; McBride S; Ganly I; Shaha AR; Sherman EJ; Tsai CJ; Kang JJ; Lee NY
Cancer; 2020 Jan; 126(2):444-452. PubMed ID: 31593317
[TBL] [Abstract][Full Text] [Related]
19. Effects of Pazopanib Monotherapy vs. Pazopanib and Topotecan Combination on Anaplastic Thyroid Cancer Cells.
Di Desidero T; Orlandi P; Gentile D; Bocci G
Front Oncol; 2019; 9():1202. PubMed ID: 31799182
[TBL] [Abstract][Full Text] [Related]
20. Anaplastic thyroid cancer.
Ranganath R; Shah MA; Shah AR
Curr Opin Endocrinol Diabetes Obes; 2015 Oct; 22(5):387-91. PubMed ID: 26313900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
